Literature DB >> 11056334

Faslodex (ICI 182780). an oestrogen receptor downregulator.

A Howell1.   

Abstract

Anti-oestrogen therapy, tamoxifen in particular, has revolutionised the treatment of breast cancer. However, the partial agonist activity of tamoxifen is associated with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance. In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11056334     DOI： 10.1016/s0959-8049(00)00241-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  8 in total

1.  Research resource: enhanced genome-wide occupancy of estrogen receptor α by the cochaperone p23 in breast cancer cells.

Authors:  Natalie E Simpson; Jason Gertz; Keren Imberg; Richard M Myers; Michael J Garabedian
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

3.  Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance.

Authors:  Fuxiao Xin; Meng Li; Curt Balch; Michael Thomson; Meiyun Fan; Yunlong Liu; Scott M Hammond; Sun Kim; Kenneth P Nephew
Journal:  Bioinformatics       Date:  2008-12-17       Impact factor: 6.937

4.  Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines.

Authors:  Denzel R Woode; Harini S Aiyer; Nicole Sie; Alan L Zwart; Liya Li; Navindra P Seeram; Robert Clarke
Journal:  Int J Breast Cancer       Date:  2012-12-31

Review 5.  P-cadherin expression in breast cancer: a review.

Authors:  Joana Paredes; Ana Luísa Correia; Ana Sofia Ribeiro; André Albergaria; Fernanda Milanezi; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  The antiestrogen ICI 182,780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy.

Authors:  Hyun Wook Cho; Rong Nie; Kay Carnes; Qing Zhou; Noaman A Q Sharief; Rex A Hess
Journal:  Reprod Biol Endocrinol       Date:  2003-08-18       Impact factor: 5.211

7.  Effects of ICI 182780 on estrogen receptor expression, fluid absorption and sperm motility in the epididymis of the bonnet monkey.

Authors:  Deshpande Shayu; C S ChennaKesava; Rama Soundarajan; A Jagannadha Rao
Journal:  Reprod Biol Endocrinol       Date:  2005-03-02       Impact factor: 5.211

Review 8.  First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

Authors:  Z-W Wong; M J Ellis
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.